Prefilled Syringes Market Size Worth $56.20 Billion By 2032 | CAGR: 10.9%

Prefilled Syringes Market Size Worth $56.20 Billion By 2032 | CAGR: 10.9%

The global pre-filled syringes market size is expected to reach USD 56.20 billion by 2032 according to a new study by Polaris Market Research. The report “Prefilled Syringes Market Share, Size, Trends, Industry Analysis Report, By Material (Glass and Plastic); By Design (Dual Chamber, Single Chamber, and Customized); By Type (Conventional, and Safety Syringes); By Application (Insulin, Vaccine, Anti-coagulant, and Others), By Regions; Segment Forecast, 2024 –2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.


The pharmaceutical industry is witnessing a rapid rise in bio-pharmaceuticals which is increasing demand for various advanced drug delivery devices, including prefilled syringes. Currently, more than 60% of the drugs in the clinical trials are biologics which needs to be administered parenterally.


Prefilled syringes (PFS) are efficient, reliable and convenient method for parenteral drug administration. These help the pharmaceutical companies to minimize drug waste and increase product life span which in turn leads to cost savings. PFS reduces the product wastage by preventing the dose overfill by four to five percent. This is especially advantageous for biological drugs as their manufacturing and product costs are too high and have low bulk manufacturing capacity. The product costs of some biologicals are as high as USD 2,000 per dose. PFS lowers the overall cost-per-dosage-unit compared to conventional syringe and vials. Hence, the demand for PFS is rising strongly in all customer segments; pharmaceutical companies, physicians and patients.


Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below:


It is estimated that nearly 50% of the diabetics live in China, India, US, Brazil and Indonesia. There is immense scope for PFS market penetration in these emerging countries due to huge patient base. Many patients are choosing to self-administer drugs in non-medical settings to reduce their healthcare and other related treatment costs. Administering a PFS involves lesser steps and lesser dexterity in comparison to the conventional needle and syringe.  


PFS is convenient to use in non-medical settings as it is ergonomic, provide the accurate dose and preserves the sterility of the drug for over 6 months. PFS are increasingly being used for self-administration by users with chronic diseases such as diabetes and rheumatoid arthritis.


Market participants such as Becton Dickinson (BD), Medpro, Haselmeier AG, Stevanato Group, Owen Mumford, SCHOTT, Unilife Corporation, OMPI, Fresenius Kabi, Catalent, Vetter Pharma International GmbH, Gerresheimer, Weigao Corporation, West Pharmaceutical Services, Inc., and Nipro Medical Corporation are some of the key players operating in the concerned market.


With surge in COVID-19 cases, the U.S. government is liable to increase domestic medical facility to cope up with the future scenario. In line with this, in May 2020, the Department of Defense (DOD) and the U.S. Department of Health and Human Services awarded a contract of worth USD 138 million to the U.S. based ApiJect Systems America to start Project Jumpstart. The project would revamp the country’s production capability, by October 2020, to be independent in manufacturing more than 100 million prefilled syringes, using blow-fill-seal aseptic plastic manufacturing technology.


Polaris Market research has segmented the prefilled syringes market report on the basis of material, design, type, application, and region

Prefilled Syringes Material Outlook (Revenue - USD Million, 2016 – 2027)

  • Glass
  • Plastic

Prefilled Syringes Design Outlook (Revenue - USD Million, 2016 – 2027)

  • Dual Chamber
  • Single Chamber
  • Customized

Prefilled Syringes Type Outlook (Revenue - USD Million, 2016 – 2027)

  • Conventional Syringes
  • Safety Syringes

Prefilled Syringes Application Outlook (Revenue - USD Million, 2016 – 2027)

  • Insulin
  • Vaccine
  • Anti-coagulant
  • Others

Prefilled Syringes Regional Outlook (Revenue - USD Million, 2016 – 2027)

  • North America
    • U.S.
    • Canada
  • Europe
    • France
    • Germany
    • UK
    • Italy
    • Spain
    • Netherlands
    • Austria
  • Asia Pacific
    • China
    • India
    • Japan
    • Malaysia
    • South Korea
    • Indonesia
  • Central & South America
    • Mexico
    • Brazil
    • Argentina
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa